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Monitoring and surveillance of antimicrobial usage in animals is a public health con‐
cern and different methods are currently discussed widely in public, science and poli‐
tics. The objective of the paper is to present the available methods of monitoring and 
to discuss possible differences in the assessment of the antibiotics treatment. Sales 
data are expressed as the average amount of substance per animal or kg live weight 
(e.g. population‐corrected unit, PCU). The number of Defined Daily Doses (nDDDvet) 
is calculated by extrapolating sales data with average animal weights and defined 
drug doses to a number of treatments theoretically applied to animals. In contrast, 
the number of Used Daily Doses (nUDDvet) displays the actual number of treatments 
which have been applied. As sales data are relatively easily obtained, they are fre‐
quently used. However, their results are influenced by the composition of the popula‐
tion and by the dose of the substances. As both may vary strongly between countries, 
direct comparison of sales data between countries may be misleading. The concept of 
analysing sales data is shown by exemplarily using the methods in the ESVAC report 
2015. The presentation of usage data in terms of nDDDvet or of nUDDvet increases 
the comparability of the data from different countries or time periods. Furthermore, 
fluoroquinolones and third‐/fourth‐generation cephalosporins which, among other 
substances, bare a potential risk for human health, are used at low doses. Hence, their 
use contributes to a sales reduction while contrasting the guidelines of prudent use. 
nDDDvet or nUDDvet have the ability to better reflect the treatment frequency and 
thus to better link antibiotics use to public health concerns. Quantification of antibi‐
otics should assist to focus on prudent use of antimicrobials to reduce the burden of 
resistant bacteria and, thus, enhance public health, animal health and animal welfare.
K E Y W O R D S
antimicrobial consumption, cephalosporins, farm animals, PCU, quinolones, technical units
1  | INTRODUC TION
The documentation of the antibiotic consumption both of humans 
and animals is an urgent global one health need (World Health 
Organization, 2015). For this, sales data are commonly used to display 
the usage of antimicrobials in animals. These data are derived from 
marketing authorization holders, wholesalers or feed mills and are 
relatively easy to obtain. An average consumption per animal can be 
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calculated by dividing the sum of sold active substances by any pop‐
ulation unit, for example, number of animals or kg biomass produced. 
Many countries report sales data and related units of measurement 
such as mg/biomass regularly (Bager et al., 2015; Belgian Veterinary 
Surveillance of Antibacterial Consumption National consumption re‐
port, ; The Public Health Agency of Sweden & National Veterinary 
Institute, 2014; Veterinary Medicines Directorate, 2012). Sales data 
are also used in projects and reported in the respective publications 
(Bondt, Jensen, Puister‐Jansen, & van Geijlswijk, 2013; Carmo et al., 
2017; Menéndez González, Steiner, Gassner, & Regula, 2010).
The project European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC) of the European Medicines Agency (EMA) 
was established in 2009 and has been reporting sales data in 
European countries since. Countries take part voluntarily and the 
most recent report from 2016 states a total of 30 countries (27 EU 
member states, 2 EEA countries as well as Switzerland) providing 
data (European Medicines Agency und European Surveillance of 
Veterinary Antimicrobial Consumption, 2018); Grave et al., 2014; . 
Results are reported in terms of population‐corrected sales in mg of 
substance per population‐corrected unit (PCU) (European Medicines 
Agency, 2017; Grave et al., 2014).
Although easily obtained, the presentation of antibiotics usage in 
terms of sales data is prone to being influenced by factors of several 
types. Both the numerators, that is, the amount of substances, as well 
as the denominator, that is, the population at risk, underlie various 
factors, which may strongly influence the outcome. Consequently, 
data from different populations, for example, countries, or time pe‐
riods cannot be compared directly and may lead to misinterpretation 
of the results (Bondt et al., 2013).
Collineau et al. (2017) recently published a detailed overview 
and discussion regarding the indicators for quantification of anti‐
microbial usage and their applications. They point out that national‐
level data are useful for certain study objectives such as monitoring 
trends over time, but only if comparability of the populations is given. 
Lekagul et al. (2018) as well as Werner, McEwen, and Kreienbrock 
(2018) also reviewed the diversity of methods for quantification.
The purpose of the present publication is to explain the pitfalls 
and consequences of using sales data for inter‐country compar‐
ison, that is, the challenges regarding the composition of animal 
husbandry forms of the countries, the different dosing regimens of 
substances and the different impact of substances regarding pub‐
lic health. To demonstrate these restrictions, the concept of ana‐
lysing sales data is shown briefly by exemplarily using the methods 
in the ESVAC report 2015 (European Medicines Agency, 2017).
Additionally, alternatives to sales data such as the quantification 
of defined or actual treatments are presented and discussed.
2  | MATERIAL S AND METHODS
Methods are described in general, details refer to the ESVAC re‐
port 2015 as example (European Medicines Agency, 2017), which is 
known to be the most comprehensive system on antibiotic sales data 
documentation in the world and has been evaluated by a large group 
of experts from the European countries.
2.1 | Population at risk
The definition of the population at risk of being treated is a crucial 
variable for which several different calculation approaches are avail‐
able (Collineau et al., 2017). One concept is to identify the biomass 
or live weight at risk of being treated by multiplying the number of 
produced or live animals with the respective expected body weight 
at typical treatment age. The expected body weight differs between 
animal species, age or production groups. Alternatively, the number of 
animals at risk of being treated can be used.
ESVAC uses the PCU (=1 kg live weight) and refers to Montforts 
(2006) regarding animal weights (Table 1) (European Medicines 
Agency, 2009; Montforts, 2006). Other publications report dif‐
ferent animal weights (e.g. Bager et al., 2015; Jensen, Jacobsen, & 
Bager, 2004; SDa expert panel, 2015; The Public Health Agency of 
Sweden & National Veterinary Institute, 2014).
ESVAC’s PCU is calculated as the sum of all animals multiplied 
with their respective body weight. The number of animals consists 
of slaughtered plus live animals (for dairy cattle, sows, horses and 
sheep).
2.2 | Sales data
The amount of antibiotics sold is expressed as amount of antimicro‐
bial substances in tonnes and is usually completed by information on 
the substance and its pharmaceutical form. The countries submit the 
number of sold packages per product and package size to ESVAC. 
The countries also provide information on name and concentration 
TA B L E  1   Average animal weights at typical age of treatment 
(European Medicines Agency, 2009; Montforts, 2006)
Animal category Weight in kg











Slaughtered sheep and goat; 






Fish Biomass slaughtered weight
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of the active substance(s). ESVAC calculates the sum of all active 
substances sold per country in tonnes.
ESVAC reports the results as mg/PCU, that is, the relation of the 
overall amount of substances to the overall PCU. In the ESVAC re‐
port 2015, the results ranged from 2.9 to 434.2 mg/PCU per country 
(European Medicines Agency, 2017).
2.3 | Quantification of defined treatments
The frequency of treatments is described by means of technical 
units to achieve comparable values. Definitions of this measure can 
be found in the literature under different similar notations, for exam‐
ple, DDD, ADD or DDDA. ESVAC’s term DDDvet is used throughout 
this publication (European Medicines Agency, 2016, 2015).
The Defined Daily Dose DDD is the dose of a substance applied 
to an animal in one day when treated with one defined dose. The 
defined dose is determined for each substance, each animal species 
and each administration route separately. Combination drugs or 
long‐acting compounds also require separate doses.
Several studies report different values of DDDs, rendering their 
results not directly comparable (Bondt et al., 2013; Callens et al., 
2012; Grave, Kaldhusdal, Kruse, Harr, & Fevang; Flatlandsmo, Knut, 
2004; Persoons et al., 2012; Postma et al., 2015). In 2016, EMA has 
published doses that are used for the examples shown in this article 
(European Medicines Agency, 2016, 2015).
The number of DDDvet (nDDDvet) is calculated by dividing the 
amount of the respective substance used by its DDD. Division of 
the nDDDvet by the population at risk (as described above, also see 
Collineau et al., 2017) results in an average nDDDvet per popula‐
tion unit, for example, per animal or per PCU. It can be displayed 
separately for each substance and/or administration route or as an 
overall result.
Formulas 1 and 2 are used to calculate the examples displayed 
below.
2.4 | Quantification of actual treatments
UDDvet is the used daily dose that is applied to an animal on one day. 
The number of UDDvet (nUDDvet) is calculated by multiplying the 
number of treated animals with the number of treatment days and the 
number of different substances applied. The sum of all nUDDvet dur‐
ing a certain time period is divided by the population at risk and results 
in the nUDDvet per animal or PCU (Chauvin, Beloeil, Orand, Sanders, 
& Madec, 2002; Menéndez et al., 2010; Obritzhauser et al., 2016; 
Persoons et al., 2012; Timmerman et al., 2006; Trauffler, Griesbacher, 
Fuchs, & Kofer, 2014; van Rennings et al., 2015).
The following formulas 3 and 4 are suitable for these means of 
calculation.
Inaccuracies occur when long‐acting compounds are used that 
are effective for more than 24 hr. Correction may be performed by 
replacing treatment duration by duration of effectiveness typical of 
this substance, but currently no internationally accepted solutions 
for this problem exist.
2.5 | Examples
To illustrate differences in the results depending on the calculation 
method used, the treatment of respiratory diseases in broilers is 
given as an example. The mg/PCU of the specific treatments is cal‐
culated following formulas 5 and 6.
2.6 | Statistical analyses
Statistical analyses were carried out with IBM SPSS Statistics version 
24. Published data of the ESVAC report 2015 were used to carry out 
the following analyses: the variable ‘animal density in PCU/km2’ was 
calculated by dividing the overall number of PCU (European Medicines 
Agency, 2017) by the area of the respective country (www.wikip edia.
com) in square kilometres. Additionally, the variable ‘percentage of the 
overall PCU related to pigs and poultry (intensive animal husbandry 
species)’ was calculated.
Variables were checked for normality by Shapiro–Wilk test as 
well as visually. ‘Population‐corrected sales in mg/PCU’ was trans‐
formed to logarithmic values (to the base of 10) to achieve normal 
distribution.
Pearson's correlation coefficient was calculated to display the cor‐
relation between the percentage of overall PCU related to pigs and 
poultry and the population‐corrected sales in mg/PCU (log). To investi‐
gate the influence of the percentage of PCU related to pigs and poultry 
as well as the animal density in PCU/km2 on the population‐corrected 
sales in mg/PCU (log), a multivariable linear regression model was 
adjusted. Values of the independent variables were centred. The an‐
imal density did not show a linear relationship to log mg/PCU but its 
cubic transformation x_cubic = x * x2 *x3 fitted well to the data. Thus, 





number of animals × average animal weight
(3)
nUDDvet=number of treated animals
× treatment days × number of substances
(4)nUDDvet∕PCU= nUDDvet
number of animals × average animal weight
(5)





number of animals × animal weight
=dose × treatment duration
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were included in the linear regression model. The impact of the model 
was evaluated by the adjusted R squared. Normality and homoscedas‐
ticity of residuals were checked visually.
3  | RESULTS
The percentage of PCU related to pigs and poultry (intensive animal 
husbandry species) as reported in the ESVAC report 2015 ranged 
from 9% to 79% (European Medicines Agency, 2017) and showed 
moderate correlation to the log population‐corrected sales in mg/
PCU (Pearson's r = .586, Figure 1).
Since a high animal density (PCU/km2) correlated with a high per‐
centage of intensive animal husbandry species (Pearson's r = .479), we 
investigated whether the percentage of intensive animal husbandry 
species or the animal density had significant effects on the overall 
population‐corrected sales in log mg/PCU. The multivariable regres‐
sion analysis (p < .001) demonstrated that the percentage of PCU 
related to intensive animal husbandry species (p < .001) as well as 
the cubically transformed animal density (p = .002 for animal density, 
p = .003 for (animal density)2, p = .010 for (animal density)3) had statis‐
tically significant effects on log mg/PCU (Table 2, Table 3).
The regression coefficient of.020 is defined as the population‐
corrected sales increased by 0.020 log mg/PCU when the percent‐
age of PCU related to pigs and poultry increased by 1 percentage 
point. The adjusted R squared of .524 indicated that more than half 
of the variation of log mg/PCU could be explained by the variables 
in the model.
3.1 | Relationship between sales, 
nDDDvet and nUDDvet
The relationship between sales, nDDDvet and nUDDvet, is displayed 
by the following example: respiratory diseases in broilers can be 
treated with different substances. As example, 100 broilers of 800 g 
live weight each must be treated either with tylosin (macrolide) or 
with a combination of lincomycin (lincosamides) and spectinomycin 
(aminoglycosides).
The veterinarian decides to apply tylosin with a dosage of 
100 mg/kg via drinking water for 3 days (recommendation: 20–
100 mg/kg for 3–5 days (Löscher, Richter, & Potschka, 2014)). 
Alternatively, the veterinarian decides for a treatment of the 
combination preparation with 17 mg/kg lincomycin and 34 mg/kg 
spectinomycin for 4 days (recommendation: 17–25 mg/kg linco‐
mycin and 34–50 mg/kg spectinomycin for 4–7 days (Löscher et 
al., 2014)). The amount of substance per PCU is calculated follow‐
ing formula 6.
Treatment with tylosin results in.
while treatment with the combination preparation results in.
The nDDDvet is calculated as introduced above (formulas 1 and 
2). It needs to be considered that the average animal weight = PCU 
=1 kg is used in these calculations instead of the actual animal 
weight = 0.8 kg. Based on the calculated usage data, treatment with 
tylosin results in 2.96 nDDDvet per PCU (Table 4) while treatment 
with the combination of lincomycin and spectinomycin results in 
5.34 nDDDvet per PCU.
The calculation of the number of UDDvet is carried out following 
formulas 3 and 4.
Therefore, the treatment of the 100 broilers results in 3.0 nUD‐




Sales data are usually reported on national level and thus summarize 
the results over all animal species and substances included. Direct 









F I G U R E  1   Relationship between the 
percentage of PCU related to pigs and 
poultry and the antibiotics usage in log 
mg/PCU following the ESVAC report 
2015 (European Medicines Agency, 2017)
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comparison of data from different populations, regions or time peri‐
ods may be influenced, among others, by two factors: the composi‐
tion of the population and the doses of the substances.
4.2 | Composition of animal populations
If countries or time periods are compared, the composition of 
the population usually differs. Regarding the technical units of 
ESVAC, this does not necessarily have an impact on the overall 
PCU. But—at least at the moment—the average antibiotics usage 
differs substantially between the species (Carmo et al., 2017; 
Obritzhauser et al., 2016; Postma et al., 2015; Schüpbach‐Regula, 
Torriani, Gassner, Stucki, & Müntener, 2009; Sjölund et al., 2016). 
Reasons for species differences are only partially due to the spe‐
cies itself—such as metabolism characteristics—but mainly result 
from different patterns regarding husbandry and type of use. 
Some animal species are kept under extensive conditions such as 
sheep and goats. Stocking densities are usually low and these spe‐
cies tend to have good health conditions as their breeding does 
not focus on high performance. Other species such as pigs and 
poultry are often farmed intensively, since their rapid growth al‐
lows for short production cycles. High stocking densities, fatten‐
ing of young animals with insufficient immune system can cause 
high infection rates in intensive farming systems. In consequence, 
the animals need to be treated more frequently. This highlights the 
special challenge of reducing antibiotics usage in intensive animal 
husbandry which includes all aspects of farm management, animal 
husbandry and genetics.
At the moment, countries with a large amount of intensive an‐
imal husbandry tend to have higher antibiotics usage than other 
countries although countries with low sales figures despite inten‐
sive animal husbandry exist (e.g. Denmark, the Netherlands). Some 
European countries have made large improvements in the last years 
and were able reduce their antibiotics usage substantially (European 
Medicines Agency, 2017). Comparisons between countries should, 
hence, be based on data stratified for animal species, age group and 
husbandry system. This will facilitate to identify countries or regions 
in which special efforts in reducing antibiotics usage are necessary. 
The challenges regarding comparisons between populations are 
discussed in detail by Collineau et al. (2017). While Collineau et al. 
(2017) provide a complete and balanced review, the intention of this 
paper is to highlight reasons for the differences between countries 
that could be prevented using nDDDAvet or nUDDAvet instead.
4.3 | Substances
Sales data must be analysed separately for each substance or sub‐
stance class due to two reasons. First, the doses differ significantly 
between substances, animal species as well as between different ad‐
ministration routes (examples given below). Second, the substances 
and substance classes differ concerning their impact on selection of 
resistant bacteria.
4.4 | Dosage
The main variables of substance selection are animal species, patho‐
gen species, affected tissue (due to pharmaceutical characteristics 
and the respective availability in tissues) and route of administration. 
The availability and the price of the pharmaceuticals also appear to 
be important as well as habit, ease of application and marketing 
strategies of products.
The dosage of colistin in terms of weight of active substance per 
kg bodyweight is 5.1 mg/kg for poultry, whereas tylosin has a dose of 
81 mg/kg (European Medicines Agency, 2016, 2015). Consequently, 
treatment with tylosin uses much more mg/PCU than treatment 
with colistin.
 Sum of squares
Degrees of 
freedom Mean squares F value p value
Regression 4.042 4 1.010 8.979 <.001
Residuals 2.813 25 0.113   
Total 6.855 29    
TA B L E  2   ANOVA table of linear 
regression analysis, log mg/PCU as 
dependent variable, percentage of PCU 
related to pigs and poultry as well as 
animal density as independent variables
TA B L E  3   Coefficients of linear regression analysis, log mg/PCU as dependent variable, percentage of PCU related to pigs and poultry as 
well as animal density (cubic transformation) as independent variables
 
Regression 
coefficients b t statistic p value
95% Confidence interval
Lower limit Upper limit
Constant 1.784 29.129 <.0001 1.658 1.910
Percentage of PCU related to pigs and poultrya  0.020 4.675 <.001 0.011 0.028
Animal density in PCU/km2a  0.076 3.455 .002 0.031 0.121
(Animal density in PCU/km2)2a  −0.002 −3.243 .003 −0.004 −0.001
(Animal density in PCU/km2)3a  0.00002 2.787 .010 0.000 0.000
aVariables were centred. Constant corresponds to 41.4% pigs and poultry at 15.97 PCU/km2, 577.22 (PCU/km2)2 and 31,937 (PCU/km2)3. 
     |  159MERLE and MEYER‐KÜHLInG
Doses also depend on the animal species. For example, tylosin 
has recommended dosages of 81 mg active substance/kg in poultry, 
12–13 mg/kg in pigs, and 13–41 mg/kg in cattle, depending on the 
administration route (European Medicines Agency, 2016). This also 
influences the amount of substance used and can cause a bias in 
comparisons between countries.
Bias can also occur as the recommendations in the Summary of 
Product Characteristics (SPCs) vary between different pharmaceuti‐
cal products, although they contain the same substance and refer to 
the same species, administration route and indication. These circum‐
stances not only affect the mg/PCU but also the nDDDvet. Solely 
the nUDDvet is not affected as it considers the used dose instead 
of a defined dose.
4.5 | Classification of substance groups
The second reason for substance‐specific analyses is that the 
usage of antimicrobials also affects the selection and distribution 
of bacterial strains that acquired resistance against specific anti‐
microbial substances (resistant bacteria). Each usage of antibiotics 
stimulates the selection of resistant bacteria and, thus, potentially 
contributes to future treatment failures in veterinary or human 
medical care. The substance classes are categorized depending 
(1) on the importance of the substance in veterinary medicine 
(e.g. if alternatives are available), (2) on the zoonotic relevance of 
the infectious diseases and (3) on the risk of transmission of re‐
sistant bacteria to humans (European Medicines Agency, 2014). 
The Advisory Group on Integrated Surveillance of Antimicrobial 
Resistance (AGISAR) of the World Health Organization (WHO) 
has recommended the restricted use of substances that are either 
the only or one out of few substances effective against a severe 
disease or that are effective against zoonotic pathogens. AGISAR 
classified the substances into one of three categories. Third‐ and 
fourth‐generation cephalosporins, macrolides, quinolones, glyco‐
peptides as well as polymyxins are categorized as ‘highest priority 
critically important drugs’ (WHO Advisory Group on Integrated 
Surveillance of Antimicrobial Resistance (AGISAR) 2017).
As some critically important substance classes such as cephalo‐
sporins and fluoroquinolones have low doses, the usage of these in‐
stead of other substance classes can cause an overall sales reduction 
while increasing the risk for public health at the same time.
4.6 | Quantification of defined treatments nDDDvet
Although defined doses are determined following the recommenda‐
tions in the respective SPCs (e.g. European Medicines Agency, 2016) 
or expert opinions, they have to be regarded as a technical unit only. 
They do not necessarily reflect the most frequently used dose of 
the substance, since the used dose also depends on the veterinar‐
ian's personal decision. With regard to interpretation, the defined 
doses should be chosen as closely as possible to the used doses. 
Scientific studies such as Joosten et al. (2019) using several ap‐
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in a multi‐country study on broiler farms revealed differences within 
and between countries. The same research consortium ‘Ecology 
from Farm to Fork Of microbial drug Resistance and Transmission’ 
EFFORT yielded similar results in pig farms (Sarrazin et al., 2019).
The calculation of defined treatments allows for comparison of 
treatment frequencies between substances. It is also possible to look 
for trends and differences between countries. For assessment of an‐
tibiotics usage in animals concerning public health aspects, possible 
shifts from undesired substance classes such as fluoroquinolones or 
third‐/fourth‐generation cephalosporins to less critical substance 
classes can be observed.
In conclusion, the number of defined treatments is well suited 
for population or time period comparison. The main challenge is to 
point out that although this form of data presentation may seem 
to reflect the number of actual substance application to animals, it 
must be regarded as technical unit which is not identical to the actual 
number of treatments. Thus, it is recommended not to be used in 
communication with farmers. Nevertheless, in some countries such 
as Denmark and the Netherlands, this method is successfully em‐
ployed for benchmarking of farms (Bager et al., 2015; SDa expert 
panel, 2016).
4.7 | Quantification of actual treatments nUDDvet
The other approach is to determine the actual number of used daily 
doses, nUDDvet. The relevant information can only be collected on 
farm level and thus requires much effort (Menéndez González et al., 
2010; Persoons et al., 2012; van Rennings et al., 2015).
Furthermore, data often originate from different sources, for ex‐
ample, farmers or veterinarians, and thus, reliability of data might be 
violated due to reporting bias. The possible (negative) consequences 
further decrease the willingness of data owners to submit data.
However, the nUDDvet is well suited for analysis and commu‐
nication of antibiotic usage on farm or veterinarian level, as its cal‐
culation is based on real treatments and can be easily understood. 
Changes of treatment frequency within a farm can be displayed 
transparently and facilitates a more direct observation by the animal 
owner and the veterinarian, for example, of the success of measures 
taken to increase animal health. Regardless of the large time expen‐
diture and effort, Germany successfully introduced a monitoring 
system in farm animals in 2014 (Bundesministerium für Ernährung 
& Landwirtschaft und Verbraucherschutz, 22013; Bundestag, 2013).
4.8 | Comparison of the different approaches
The results of the three calculation methods differ. If the substance 
is unknown, it is not possible to infer treatment frequency from the 
amount of substance used. Differences between nDDDvet and nUD‐
Dvet rely on differences between defined and actual dose or on dif‐
ferences between average and actual animal weight. Discrepancies 
between used and defined doses do not imply that an inappropriate 
dose was chosen, as appropriate dosing depends on certain condi‐
tions within the animal group such as age, health status or resistance 
situation. The discussion of this paper focuses on the possible dif‐
ferences in the assessment of the antibiotics treatment depending 
on the calculation approach. For a complete review, see Collineau 
et al. (2017).
Under practical conditions, decisions of veterinarians to treat an‐
imal flocks take different perspectives into account, the complexity 
of which is illustrated by the example of treating respiratory diseases 
such as Mycoplasma infection in broilers given above: the adminis‐
tration of tylosin uses the highest amount of substance, while treat‐
ment with the combination formula Lincomycin + Spectinomycin 
yields higher values of nDDDvet and nUDDvet. The responsible vet‐
erinarian is aware of these facts, but he or she needs to consider the 
results of microbiological investigations, severity of flock infestation 
including animal welfare and also consumer protection. All antimi‐
crobial substance classes including those mentioned in the example 
given above need to be classified as critical considering both veteri‐
nary and human medicine. The WHO has classified macrolides ‘high‐
est priority critically important antimicrobials’ and EMA recommends 
a restrictive use of this substance class due to possible selection for 
macrolide‐resistant Campylobacter in animals (European Medicines 
Agency, 2017; WHO Advisory Group on Integrated Surveillance of 
Antimicrobial Resistance (AGISAR) 2017; ; ).
However, the European Union´s report on antimicrobial resis‐
tance of zoonotic and indicator bacteria from humans, animals and 
food in 2016 reflects a low overall resistance for Campylobacter 
jejuni isolated from broilers against the important macrolide eryth‐
romycin, that is, 1.3% in average for 24 Member States (European 
Food Safety Authority & European Centre for Disease Prevention 
and Control, 2018).
Lincosamides such as Lincomycin are classified ‘highly import‐
ant’ and used to treat important bacteria such as Enterococcus, 
Staphylococcus (MRSA) in human intensive care units. 
Aminoglycosides are preliminary rated in category 2 because a 
risk assessment has not yet been carried out (European Medicines 
Agency, 2014). In general, combination preparations display a higher 
risk for selection of resistant bacteria and thus should be avoided 
following guidelines of prudent use (European Commission, 2015). 
In summary, decision‐making remains difficult for the practitioner.
In conclusion, the assessment of antibiotics usage in animals is 
not straightforward. Some measures seem to be more precise con‐
cerning the frequency in which an animal is treated with antimicro‐
bials on average. As these measures require much time and effort, 
they are applicable for studies with a limited (representative) sample 
size and may include reporting bias. Thus, the results underlie uncer‐
tainty and bias.
As sales data can be made available as complete and unbiased 
datasets by many countries, they are currently the best choice for 
comparisons between countries (Grave et al., 2014). This approach 
facilitates sampling of respective data and thus encourages coun‐
tries to implement a monitoring system. It represents the necessary 
first step which is ideally followed by more detailed monitoring and 
surveillance systems focusing on the reduction of antimicrobial use 
in general or of critically important antimicrobials in the context of 
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public health. EMA already initiated data collection activities on spe‐
cies level enabling the calculation of nDDDvet for different animal 
species/category separately (European Medicines Agency, 2018). 
As explained above, this change in methods will contribute to data 
stratification for animal species/categories and will additionally con‐
trol the effects of substances.
Recently, several reviews have been published that discuss the 
methods available and their applications seriously. Interested read‐
ers may refer to Collineau et al. (2017) and to Werner et al. (2018).
Regardless of the method of data collection, monitoring of the 
antibiotics usage must be regarded as a tool to observe changes in 
the pattern of antibiotics use. The main goal is to reduce the risk 
for public health which requires the distinction between substances. 
Monitoring and surveillance should not only focus on a general re‐
duction of antibiotics use. The risk of selection and distribution of 
resistant bacteria should also be minimized while protecting animal 
health and animal welfare at the same time. It is the task of veter‐
inarians, animal owners, scientists as well as authorities to develop 
applicable approaches to enhance animal health and thus reduce the 
need of antimicrobials. The quantification of antibiotics usage in this 
context is only a tool and should not be misinterpreted as objective. 
Actions should focus on prudent use to reduce the burden of resis‐
tant bacteria and thus enhance not only public health but also animal 
health and welfare.
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